Latterell Venture Partners

LVP Portfolio Companies

Biotechnology

CellBio Sciences

Calistoga was recently acquired by Gilead Pharmaceuticals for total proceeds of up to $600 Million.  The company was a cancer pharmaceutical company developing cancer treatments targeting PI3 Kinase. 

                        

 

 

Cellective Therapeutics

Cellective was acquired by Medimmune for proceeds of up to $175 million. Cellective was developing several new pharmaceuticals treating B Cell related cancers and immune diseases. The technology is based on research by Founder Tom Tedder, Chairman of Immunology at Duke University.

 

 

Evoke is a specialty pharmaceutical company developing a portfolio of products for G.I. applications. The company completed its IPO in September 2013 and trades under the symbol EVOK.

www.evokepharma.com

 

 

ForteBio

ForteBio was recently acquired by Pall Corporation for $159 million.  ForteBio deveoped and marketed a new biotech research instrument for the rapid measurement of molecular binding useful in biopharmaceutical R&D.

www.fortebio.com

 

 

 

IntegenX is commercializing a new generation rapid DNA analysis technology.

www.integenx.com

 

 

 

Meritage was a specialty pharmaceutical company developing products to treat Eosinophilic Esophagitis and potentially other immune disorders. The company was acquired by Shire Pharmaceuticals in 2015 for proceeds of up to $245 million.

www.meritagepharma.com

 

 

Naurex was developing several next generation depression pharmaceuticals providing significant improvements over current drugs. The company was acquired in August 2015 for $560M million cash upfront plus additional future milestone payments.

                                      www.naurex.com

 

Neuraltus is a neuropharmaceutical company with a portfolio of products treating Parkinsons, ALS, and other neurological diseases.

www.neuraltus.com

 

OncoMed Pharmaceuticals

 

 

OncoMed is developing a new class of cancer therapeutics targeting cancer precursor cells.  OncoMed completed an IPO in July 2013 and trades under the symbol OMED.

www.oncomed.com

 

 

ProteinSimple was acquired by Bio-Techne Corporation for $300 milliion in August 2014.  The company developed and marketed a variety of biomedical research instruments which enable the rapid analysis of cellular components for use in biomedical research and pharmaceutical development. 

www.proteinsimple.com

Proteolix

Proteolix was acquired by Onyx Pharmaceuticals for proceeds of up to $851 million.  The company was developing a new category of cancer therapeutics which target the proteasome. The founding team was from Amgen, Merck, Caltech and Yale.

www.proteolix.com

TetraLogic is developing a new generation of cancer therapeutics based on key discoveries by Professor Yigong Shi at Princeton, relating to apoptosis.  The company completed an IPO in December 2013 and trades under the symbol  TLOG.

www.tetralogicpharma.com

 

Viracta is developing therapeutics to treat viral induced tumors.

www.viracta.com

 

 

 

Medical Device

Ensure Medical

Ensure was acquired by Johnson & Johnson for proceeds of up to $90 million. The company developed a new bio-erodable femoral closure device to seal the puncture wounds resulting from the millions of interventional cardiology procedures performed each year. The founders include leading engineers from Boston Scientific.

Inova Labs

Inova Labs was recently acquired by ResMed.  It developed and commercialized a new generation of lightweight Portable Oxygen Concentrators for patients with lung disorders who need continuous supplemental oxygen. 

www.inovalabs.com

 

Pathway was recently acquired by Medrad, a division of Bayer, for $125 milliion.  Pathway developed and marketed an impressive new atherectomy device for treating peripheral artery disease.

www.pathwaymedical.com

ProMed, Inc.

ProMed is developing a new generation of large hole closure devices for use in interventional cardiology procedures.

 

Pulmonx developed and is marketing a new category of diagnostic and treatment devices to treat lung disorders such as COPD.

www.pulmonx.com

 

Revascular Therapeutics, Inc.

Revascular Therapeutics was recently acquired by Boston Scientific.  The company developed an impressive new percutaneous device to re-open chronically occluded vessels which received FDA marketing approval prior to the acquisition.

 

Transcend is developing a pioneering new glaucoma treatment device with impressive clinical results reducing intra-ocular pressure.  The company was recently acquired by Alcon/Novartis for proceeds of up to $740 Million.

www.transcendmedical.com

 

 

Healthcare Information Technology

CellBio Sciences

 

 

PerceptiMed is developing advanced instruments and analytical tools to assist pharmacies dispensing pharmaceuticals to patients.

 

 

www.perceptimed.com

 

 

 

Copyright © 2017 by Latterell Venture Partners

LVP is Registered in the US Patent and Trademark Office